Tandem Diabetes Care (TNDM) Cash from Operations Growth (5y) (2018 - 2026)
Tandem Diabetes Care (TNDM) Cash from Operations Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.47 Bn | 176.17 Bn | 6.27 Bn |
| 2 | Stryker | 129.01 Bn | 126.14 Bn | 3.81 Bn |
| 3 | Medtronic | 108.97 Bn | 99.75 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.46 Bn | 67.01 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.40 Bn | 44.73 Bn | 1.29 Bn |
| 6 | Dexcom | 28.37 Bn | 27.25 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.36 Bn | 26.07 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - |
| 9 | Koninklijke Philips | 25.46 Bn | 22.33 Bn | 2.07 Bn |
| 10 | Tandem Diabetes Care | 1.15 Bn | 575.74 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.36% |
| Dec 31, 2025 | -8.47% |
| Sep 30, 2025 | -10.71% |
| Jun 30, 2025 | -21.18% |
| Mar 31, 2025 | 2.39% |
| Dec 31, 2024 | -11.23% |
| Sep 30, 2024 | 3.07% |
| Jun 30, 2024 | -28.31% |
| Mar 31, 2024 | -14.16% |
| Dec 31, 2023 | -20.21% |
| Sep 30, 2023 | 15.05% |
| Jun 30, 2023 | 1.22% |
| Mar 31, 2023 | -8.35% |
| Dec 31, 2022 | 20.11% |
| Sep 30, 2022 | 26.65% |
| Jun 30, 2022 | 19.83% |
| Mar 31, 2022 | 21.64% |
| Dec 31, 2021 | 28.07% |
| Sep 30, 2021 | 31.15% |
| Jun 30, 2021 | 32.87% |